Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing.

Abstract excerpt

BACKGROUND: Avapritinib is a selective tyrosine kinase inhibitor approved for advanced PDGFRA exon 18-mutant gastrointestinal stromal tumors (GIST), including the imatinib-resistant D842V variant. However, its role in the preoperative setting for localized, resectable disease has not been defined. METHODS: We conducted a retrospective two-center exploratory case series of eight patients with localized, resectable...

Topics

Join the communities discussing this publication.

• Feasibility Studies
• Gastrointestinal Neoplasms
• Gastrointestinal Stromal Tumors
• Protein Kinase Inhibitors
• Pyrazoles